平台试验中 Concurrent Controls 的整合一致的点估计与假设检验框架
针对主方案平台试验中随机化比例可随时间变化、且该变化未必依赖累积结局数据的特点,本文研究逆概率治疗加权与按时间段加权两类估计量之间的关系,推导出该类中的最优估计量,并给出基于观测数据近似未知权重的实用构建方法;模拟研究显示所提方法可控制I类错误率并降低估计偏倚,在计算效率下获得满意的把握度与均方误差,点估计与假设检验结论一致;方法进一步应用于 Accelerating COVID-19 Therapeutic Interventions and Vaccines 平台试验。
要点
- 平台试验随机化比例可随时间变化,分析应考虑不同随机化比例的时间段。
- 逆概率治疗加权与按时间段加权两类估计量存在联系,可推导出最优估计量。
- 模拟研究显示所提方法可控制I类错误率并降低估计偏倚。
核心结论
- 所提框架能为点估计与假设检验提供一致的结论,这对临床试验结果的解读至关重要。
- 模拟研究表明所提方法可控制I类错误率并降低估计偏倚,并在计算效率下获得满意的把握度与均方误差。
研究设计与样本
- 本文为统计方法学研究,考察平台试验主方案下随机化比例随时间变化时点估计与假设检验的整合框架。
- 研究推导了逆概率治疗加权与按时间段加权两类估计量之间的关系,并在该类中推导最优估计量。
- 采用模拟研究评估所提方法的I类错误率、估计偏倚、把握度与均方误差。
- 所提方法进一步应用于 Accelerating COVID-19 Therapeutic Interventions and Vaccines 平台试验。
主要发现
- 研究具体考察了逆概率治疗加权与按时间段加权两类估计量之间的关系。
- 研究在该类估计量中推导出最优估计量以提升效率。
- 研究给出了基于观测数据构建估计量以近似该未知权重的实用指导。
- 研究还考察了所提方法与加权最小二乘之间的联系。
- 模拟研究显示所提方法可控制I类错误率并降低估计偏倚,并在计算效率下获得满意的把握度与均方误差。
关键数值与推荐
- 建议分析应考虑随机化比例不同的时间段,可采用逆概率治疗加权或按时间段加权的方法。
临床怎么用
- 原文建议分析应纳入随机化比例不同的时间段,并给出逆概率治疗加权或按时间段加权等可能方法。
- 原文提供了基于观测数据构建估计量以近似未知权重的实用指导。
- 所提方法进一步应用于 Accelerating COVID-19 Therapeutic Interventions and Vaccines 平台试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A platform trial with a master protocol provides an infrastructure to ethically and efficiently evaluate multiple treatment options in multiple diseases. Given that certain study drugs can enter or exit a platform trial, the randomization ratio is possible to change over time, and this potential modification is not necessarily dependent on accumulating outcomes data. It is recommended that the analysis should account for time periods with different randomization ratios, with possible approaches such as inverse probability of treatment weighting or a weighted approach by the time period. To guide practical implementation, we specifically investigate the relationship between these two estimators, and further derive an optimal estimator within this class to gain efficacy. Practical guidance is provided on how to construct estimators based on the observed data to approximate this unknown weight. The connection between the proposed method and the weighted least squares is also studied. We conduct simulation studies to demonstrate that the proposed method can control type I error rate with a reduced estimation bias, and can also achieve satisfactory power and mean squared error with computational efficiency. Another appealing feature of our framework is the ability to provide consistent conclusions for both point estimation and hypothesis testing. This is critical to the interpretation of clinical trial results. The proposed method is further applied to the Accelerating COVID-19 Therapeutic Interventions and Vaccines platform trial.
引用
- Zhan T, Zhang J, Shu L, et al. An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing With Concurrent Controls in Platform Trials. Stat Med. 2025. PMID: 40689932. doi:10.1002/sim.70196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。